Ma-Lek Clinical Sp. z o.o.
- Address
- lock Available on a paid plan
Immune System Diseases
Ma-Lek Clinical Sp. z o.o. in Katowice is running a series of studies that explore how immune system modulation can alter the course of multiple sclerosis, an autoimmune disorder of the central nervous system. The trials aim to test new biologic agents and compare them with established oral treatments to improve efficacy and safety.
- Monoclonal antibodies targeting B‑cells
- Head‑to‑head comparisons with standard disease‑modifying therapies
- Extended safety and tolerability monitoring
- Biomarker‑driven outcomes such as serum neurofilament levels
The site supports 17 clinical trials with four investigators, reflecting a strong commitment to advancing therapies for immune‑mediated disease.
Musculoskeletal Diseases
Several protocols at the Katowice facility examine the impact of multiple sclerosis on muscle tone and movement, including the management of spasticity. By testing novel agents and dosing regimens, researchers seek to enhance functional ability and reduce disability related to muscle stiffness.
- Quantitative assessment of spasticity reduction
- Improvement in hand dexterity and 9‑hole peg test performance
- Gait and balance measurements
- Patient‑reported outcomes on daily activity
These investigations complement the broader MS program, contributing to a holistic approach that addresses both neurological and musculoskeletal challenges.
Nervous System Diseases
The core of the research portfolio focuses on relapsing‑remitting multiple sclerosis and its progressive variants, such as primary progressive multiple sclerosis. Trials are designed to evaluate the ability of new compounds to reduce new magnetic resonance imaging lesions, delay disability progression, and confirm long‑term safety.
- Reduction of gadolinium‑enhancing MRI lesions
- Delay of confirmed disability progression
- Higher‑dose versus standard‑dose efficacy comparisons
- Long‑term safety and tolerability assessments
With 17 active studies and a dedicated team of four investigators, Ma‑Lek Clinical contributes valuable data to the European MS research landscape.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1F. Hoffmann-La Roche AG1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1F. Hoffmann-La Roche AG5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ma-Lek Clinical Sp. z o.o.
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 70 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 6 | Unknown | 2019-09-19 | 2026-02-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.